These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 22251419)

  • 1. Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation.
    Chey WD; Drossman DA; Johanson JF; Scott C; Panas RM; Ueno R
    Aliment Pharmacol Ther; 2012 Mar; 35(5):587-99. PubMed ID: 22251419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation.
    Johanson JF; Drossman DA; Panas R; Wahle A; Ueno R
    Aliment Pharmacol Ther; 2008 Apr; 27(8):685-96. PubMed ID: 18248656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome--results of two randomized, placebo-controlled studies.
    Drossman DA; Chey WD; Johanson JF; Fass R; Scott C; Panas R; Ueno R
    Aliment Pharmacol Ther; 2009 Feb; 29(3):329-41. PubMed ID: 19006537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety.
    Johanson JF; Ueno R
    Aliment Pharmacol Ther; 2007 Jun; 25(11):1351-61. PubMed ID: 17509103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lubiprostone for constipation and irritable bowel syndrome with constipation.
    Tuteja AK; Rao SS
    Expert Rev Gastroenterol Hepatol; 2008 Dec; 2(6):727-33. PubMed ID: 19090733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lubiprostone for chronic idiopathic constipation and irritable bowel syndrome with constipation.
    Saad R; Chey WD
    Expert Rev Gastroenterol Hepatol; 2008 Aug; 2(4):497-508. PubMed ID: 19072397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of novel promotility and prosecretory agents for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation.
    Gale JD
    Adv Ther; 2009 May; 26(5):519-30. PubMed ID: 19444393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lubiprostone: chronic constipation and irritable bowel syndrome with constipation.
    Lacy BE; Chey WD
    Expert Opin Pharmacother; 2009 Jan; 10(1):143-52. PubMed ID: 19236188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety evaluation of lubiprostone in the treatment of constipation and irritable bowel syndrome.
    Chamberlain SM; Rao SS
    Expert Opin Drug Saf; 2012 Sep; 11(5):841-50. PubMed ID: 22834474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation.
    Johanson JF; Morton D; Geenen J; Ueno R
    Am J Gastroenterol; 2008 Jan; 103(1):170-7. PubMed ID: 17916109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety.
    Chey WD; Lembo AJ; Lavins BJ; Shiff SJ; Kurtz CB; Currie MG; MacDougall JE; Jia XD; Shao JZ; Fitch DA; Baird MJ; Schneier HA; Johnston JM
    Am J Gastroenterol; 2012 Nov; 107(11):1702-12. PubMed ID: 22986437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lubiprostone--a novel treatment for irritable bowel syndrome with constipation.
    Owen RT
    Drugs Today (Barc); 2008 Sep; 44(9):645-52. PubMed ID: 19137119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lubiprostone for the treatment of functional constipation in children.
    Hyman PE; Di Lorenzo C; Prestridge LL; Youssef NN; Ueno R
    J Pediatr Gastroenterol Nutr; 2014 Mar; 58(3):283-91. PubMed ID: 24048162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lubiprostone (Amitiza) for irritable bowel syndrome with constipation.
    Med Lett Drugs Ther; 2008 Jul; 50(1290):53-4. PubMed ID: 18617872
    [No Abstract]   [Full Text] [Related]  

  • 15. A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation.
    Tack J; Müller-Lissner S; Bytzer P; Corinaldesi R; Chang L; Viegas A; Schnekenbuehl S; Dunger-Baldauf C; Rueegg P
    Gut; 2005 Dec; 54(12):1707-13. PubMed ID: 16020489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lubiprostone: pharmacokinetic, pharmacodynamic, safety and regulatory aspects in the treatment of constipation-predominant irritable bowel syndrome.
    Raschi E; De Ponti F
    Expert Opin Drug Metab Toxicol; 2014 Feb; 10(2):293-305. PubMed ID: 24387275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial.
    Ducrotte P; Dapoigny M; Bonaz B; Siproudhis L
    Aliment Pharmacol Ther; 2005 Feb; 21(4):435-44. PubMed ID: 15709995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lubiprostone: RU 0211, SPI 0211.
    Drugs R D; 2005; 6(4):245-8. PubMed ID: 15991886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic evaluation of linaclotide for the treatment of adult patients with irritable bowel syndrome with constipation in the United States.
    Huang H; Taylor DC; Carson RT; Sarocco P; Friedman M; Munsell M; Blum SI; Menzin J
    J Med Econ; 2015 Apr; 18(4):283-94. PubMed ID: 25333331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lubiprostone: in constipation-predominant irritable bowel syndrome.
    Carter NJ; Scott LJ
    Drugs; 2009 Jun; 69(9):1229-37. PubMed ID: 19537839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.